On January 22, 2024, amendments to the Food and Drug Administration (FDA) regulations (21 CFR 50) covering Institutional Review Boards (IRBs) were finalized and implemented. The amendments added a new section, 50.22, that allows for exceptions to informed consent requirements for minimal-risk research. While the addition of section 50.22 harmonizes FDA IRB regulations with the […]